Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

(2012) Sui Zhang et al.   NATURE MEDICINE

Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks

(2012) Cole Trapnell et al.   Nature Protocols

Anthracyclines, HER2, and TOP2A: the verdict

(2011) Hervé R Bonnefoi   LANCET ONCOLOGY

The evolution of gene expression levels in mammalian organs

(2011) David Brawand et al.   NATURE

Should anthracyclines and dexrazoxane be used for children with cancer?

(2010) Elvira C van Dalen et al.   LANCET ONCOLOGY

Topoisomerase II -dependent and -independent apoptotic effects of dexrazoxane and doxorubicin

(2009) T. Yan et al.   MOLECULAR CANCER THERAPEUTICS

The Dihydroorotase Inhibitor 5-Aminoorotic Acid Inhibits the Metabolism in the Rat of the Cardioprotective Drug Dexrazoxane and Its One-Ring Open Metabolites

(2008) P. E. Schroeder et al.   DRUG METABOLISM AND DISPOSITION

Deferiprone Does Not Protect against Chronic Anthracycline Cardiotoxicity in Vivo

(2008) O. Popelova et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Topoisomerase levels determine chemotherapy responsein vitroandin vivo

(2008) Darren J. Burgess et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy

(2008) Elke Martin et al.   TOXICOLOGY

Distinct roles of Topoisomerase II isoforms: DNA damage accelerating α, double strand break repair promoting β

(2007) Raj Kumar Mandraju et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS